Navigation Links
Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC

OWINGS MILLS, Md., July 26, 2012 /PRNewswire/ -- Jason Pharmaceuticals, Inc. (the "Company") a subsidiary of Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs, today announced that it has reached a proposed consent agreement with the Federal Trade Commission ("FTC"), resolving the FTC's non-public investigation of certain statements in the Company's advertising for its weight-loss programs.   

(Logo: )

The new agreement will replace a previous consent order entered into by the Company and the FTC in 1992.  The FTC expressed concern that some of the Company's advertising contained claims which were not compatible with current standards for substantiation.  For example, in line with the FTC's recently published consumer research, the FTC objected to the Company's use of the words "up to" in conjunction with advertised weight loss claims. 

As a leader in the weight loss industry, the Company remains committed to fairly providing consumers with as much information as possible, and has agreed to modify certain advertising claims in this regard.  In addition, the Company has agreed to ensure that its clinical studies meet the protocol contained in the proposed consent agreement.  The Company agreed to pay a civil penalty of $3.7 million, without conceding any wrongdoing or liability, to resolve the FTC's concerns and avoid protracted legal proceedings.  The proposed consent agreement must be accepted by the FTC and submitted for approval to a federal district court before it becomes effective.

Conference Call

In a separate news release issued today, Medifast, Inc. announced its second quarter 2012 financial results.  Medifast will host a conference call for investors to discuss and to review its second quarter results at 4:30 p.m. ET today.  Participants from Medifast will be Michael C. MacDonald, Executive Chairman and Chief Executive Officer, Brendan Connors, Chief Financial Officer, and Margaret Sheetz, President and Chief Operating Officer.

The call will be broadcast live over the Internet hosted at the Investor Relations section of Medifast's website at, and will be archived online through August 9, 2012. In addition, listeners may dial (877) 705-6003.

A telephonic playback will be available from 7:30 p.m. ET, July 26, 2012, through August 9, 2012. Participants can dial (877) 870-5176 to hear the playback and enter passcode 397537.

About Medifast

Medifast, Inc. (NYSE: MED) is a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs.  The Medifast brand has been recommended by over 20,000 doctors and used by over one million clients since 1980. The Company is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by researchers from major university teaching hospitals. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) the Take Shape for Life personal coaching division, 3) medically supervised Medifast Weight Control Centers, and 4) a national network of wholesale physicians and medical practices. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, please visit

Forward Looking Statements
Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Associates and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward- looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.


SOURCE Medifast, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avion Pharmaceuticals, LLC., Launches Prenate Mini
2. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at
3. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at on July 12th
4. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
5. Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
6. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
7. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
8. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
9. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... the addition of the  "Global Drug ...  report to their offering.  --> ... addition of the  "Global Drug Device ... to their offering.  --> ...
(Date:11/24/2015)... -- The hope of bearing a child ... cycles. After failure of over 15 IVF cycles, Mrs. ... hopes that she would be able to conceive ever. But finally optimism prevailed as she ... of over 15 IVF cycles. India ... one last attempt with Gaudium IVF Center in New ...
(Date:11/24/2015)... Nov. 25, 2015 WuXi PharmaTech (Cayman) Inc. ... leading open-access R&D capability and technology platform company serving ... in China and ... an extraordinary general meeting of shareholders held today, the ... authorize and approve the previously announced agreement and plan ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to ... for dental implants at her Mississauga, ON practice. Dr. Williams has been ... placement of dental implants. , Missing teeth can lead to a variety of ...
(Date:11/24/2015)... ... , ... In an article published November 12th by Obesity News ... or are not eligible for bariatric surgery. The article explains that candidates for weight ... 100 pounds overweight, or have a BMI of 35 and over with at least ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Preparing for the ... – 3:00 p.m. EST, , FDA has long asserted that design ... apply to performing the tests and do not meet the device regulations. , Come ...
(Date:11/24/2015)... FL (PRWEB) , ... November 24, 2015 , ... In ... a growing epidemic as deaths from prescription opioids in the United States grew 400 ... cocaine. In 2013 alone, opioids were involved in 37 percent of all fatal drug ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s leading ... holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is designed ... way. The location is scheduled to operate through Dec. 24. , Holiday Pop-Up Clinic ...
Breaking Medicine News(10 mins):